1. People's Republic of China Stocks

  2. •

    Healthcare

  3. •

    Medical - Instruments & Supplies
Blue Sail Medical Co.,Ltd.

Blue Sail Medical Co.,Ltd.

002382.SZ
Blue Sail Medical Co.,Ltd.CN flagShenzhen Stock Exchange
5.22
CNY
-0.13
- -
5.26BMarket Cap
Blue Sail Medical Co.,Ltd.
002382.SZ
(Shenzhen Stock Exchange)

Recent

price

5.22

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
1.39
1.93
2.73
2.84
3.23
3.1
2.63
3.22
3.6
3.62
8.14
7.93
4.87
4.85
6.17
5.75
5.84
Revenue per Share
0.09
0.06
0.1
0.1
0.13
0.35
0.37
0.41
0.47
0.51
1.82
1.13
-0.37
-0.56
-0.44
-0.76
-0.4
Basic EPS, GAAP
-0.42
-0.59
-0.44
-0.34
0.16
0.44
0.13
-0.06
0.28
0.44
2.55
-0.33
-0.4
-0.83
-0.63
-0.1
-0.71
Free Cash Flow per Basic Share
0.01
0.04
0.04
0.11
0.08
0.11
0.2
0.21
0.21
0.14
0.29
0.47
0.06
0.51
0.18
0.17
0.16
Dividend per Share
0.53
0.59
0.92
1
1.08
1.31
1.97
2.16
2.35
2.25
3.87
4.42
4.07
3.08
2.67
1.86
2.45
Book Value per Share
1.96
1.77
1.65
1.58
1.99
2.24
2.46
2.72
0.39
0.81
3.3
5.93
5.55
4.35
4.82
4.2
4.45
Tangible Book Value per Share
448
484
488
470
475
486
489
490
738
961
966
1,023
1,006
1,015
1,013
999
1,041
Basic Weighted Avg Shares
622
934
1,333
1,335
1,535
1,509
1,289
1,576
2,653
3,476
7,869
8,109
4,900
4,927
6,253
5,740
6,078
Sales/Revenue/Turnover
7.33
3.85
5.63
4.23
5.74
14.51
14.07
18.23
15.19
18.77
52
32.03
-10.75
-9.54
-2.19
-2.94
-2.18
Operating Margin (%)
12
20
32
41
58
45
45
52
135
186
214
332
489
525
526
573
- -
Depreciation Expense
40
29
51
47
62
170
181
201
347
490
1,758
1,156
-372
-568
-446
-759
-414
Net Income, GAAP
14.38
14.84
20.99
21.76
15.43
25.11
18.06
20.36
0.72
9.86
12.65
14.22
- -
- -
- -
- -
- -
Effective Tax Rate (%)
6.49
3.11
3.84
3.52
4.02
11.28
14.05
12.75
13.07
14.11
22.35
14.25
-7.6
-11.54
-7.13
-13.22
-6.81
Profit Margin (%)
646
414
125
21
310
465
566
374
999
787
3,511
3,157
2,144
-139
2,380
-968
-697
Working Capital
- -
- -
- -
153
- -
- -
- -
- -
2,436
1,944
3,404
2,928
2,842
1,826
2,667
626
576
LT Debt
904
917
962
984
1,046
1,184
1,300
1,428
7,800
8,463
9,817
10,536
10,552
9,548
10,067
9,461
9,905
Total Equity
6.58
3.27
5.33
3.33
5.46
13.12
11.99
16.43
6.14
4.97
25.95
15.06
- -
- -
- -
- -
- -
Return on Invested Capital (%)
16.56
9.79
11.06
7.14
9.53
24.53
22.76
19.32
12.56
9.96
25.25
14.44
- -
- -
- -
- -
- -
Return on Capital (%)
19.36
11.1
13.92
10.25
12.55
29.56
22.65
19.89
24.81
25.17
59.56
27.96
-8.64
-15.74
-15.29
-33.3
-15.02
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
ST Debt
1,101
1,957
4,524
LT Borrowings
2,654
2,085
564
LT Finance Leases
13
14
12
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,007
1,007
1,007
Market Capitalization
5,075
5,154
5,830

Working Capital

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
Total Current Assets
5,394
5,709
5,429
Cash, Cash Equivalents & STI
2,342
2,770
2,547
Accounts Receivable, Net
1,265
1,180
1,134
Inventories
1,228
1,211
1,178
Total Current Liabilities
3,015
3,684
6,126
Payables & Accruals
- -
- -
- -
ST Debt
1,101
1,957
4,524
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
48.77%
-0.53%
-6.03%
Free Cash Flow
-56.28%
-18.63%
-85.07%
Net Income, GAAP
32.49%
-13.02%
70.32%
Sales/Revenue/Turnover
21.62%
-3.46%
-8.21%
Total Cash Common Dividend
88.97%
130.67%
-5.1%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1,455
1,551
1,649
1,599
6,253
2025
1,528
1,303
1,558
- -
5,740
2026
1,625
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.1
- -
- -
- -
-0.44
2025
0.08
- -
- -
- -
-0.76
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.03
- -
- -
- -
0.18
2025
0.02
- -
- -
- -
0.17
2026
- -
- -
- -
- -
- -
Similar Companies
Vizionfocus Inc. (4771.TW)
Baxter International Inc. (BTL.DE)
Universal Vision Biotechnology Co., Ltd. (3218.TWO)
Elekta AB (publ) (EKTA-B.ST)
Hear AtLast Holdings, Inc. (HRAL)
Sartorius AG (SUVPF)
Business
Blue Sail Medical Co., Ltd. (002382.SZ) manufactures and sells medical devices and health protection products principally in China and internationally. The company operates four primary business units offering healthcare protective products including disposable medical gloves such as latex, nitrile, PVC, and TPE/CPE varieties; cardio and neurovascular interventional devices including cardiovascular stents like BioFreedom polymer- and carrier-free drug-coated stents and EXCEL biodegradable drug-eluting stents, heart valves, neuro intervention, and peripheral intervention products; minimally invasive surgery equipment including endoscopic staplers, ultrasonic scalpels, general surgical instruments, and innovative therapy instruments; and medical healthcare supplies including first-aid kits, medical first-aid bags, family disaster prevention emergency kits, epidemic prevention kits, reflective vests, masks, and medical dressings. Bluesail Medical was founded in 2002 and is headquartered in Zibo, Shandong Province, China, with over 70 subsidiaries across more than 20 countries including production sites in Germany, Singapore, Vietnam, and China, and R&D centers in Germany, Shanghai, Singapore, and the United States; its products serve over 130 countries competing with global leaders such as Abbott, Boston Scientific, and Medtronic. In recent developments, the company's cardiovascular and cerebrovascular business unit Blue Sail Biosensors completed a record RMB 1 billion Series A funding round in 2024 comprising RMB 900 million in January and an additional RMB 100 million in May with investors including Beijing New Aerotropolis to accelerate strategic expansion in high-end medical devices and establish a northern headquarters platform; its protective business narrowed losses significantly in early 2024 with a Q2 turnaround to profitability while cardiovascular sales grew 12% in H1 with improved gross margins.